All In Biotech

Drug Trial Radar · NCT00954707

CYPRESS - CYPHER for Evaluating Sustained Safety

A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)

Last checked: Nov 19, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownResults posted on the registryPivotal-lookingRandomized with 2,509 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,509

Actual

Start

Aug 2009

Primary completion

Jan 2012

Study completion Mar 2016

Sponsor

Lead sponsor
Cordis US Corp.Industry
Sponsor type
Industry
First posted
Aug 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)

Conditions

  • Coronary Artery Disease

Interventions

  • Clopidogrel & Aspirin, Prasugrel & AspirinDrug

    This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.

  • Placebo & AspirinDrug

    This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: the Rate of Target Lesion Failure (TLF)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals, Case Medical Center (Cleveland)

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.